摘要
目的:分析探讨非肌层浸润性膀胱癌患者采取经尿道等离子电切术结合吉西他滨膀胱灌注治疗的具体方法及实际治疗效果。方法:针对笔者所在医院2016年1月-2018年12月收治的68例非肌层浸润性膀胱癌患者进行研究,将患者随机分为两组,各34例。所有患者均在院接受经尿道等离子电切术治疗,观察组结合吉西他滨,对照组结合吡柔比星,分析对比两组治疗效果。结果:观察组治疗后不良反应发生率为5.9%,低于对照组的29.4%,差异有统计学意义(<0.05)。在随访期间,两组均无死亡病例,观察组1年复发率为14.7%(5/34),对照组为11.8%(4/34),差异无统计学意义(P>0.05)。结论:经尿道等离子电切术结合吉西他滨膀胱灌注治疗能够良好控制非肌层浸润性膀胱癌再次复发,并且在安全性方面也优于吡柔比星。
Objective:To analyze and discuss the specific method and actual therapeutic effect of transurethral plasmakinetic resection combined with Gemcitabine bladder perfusion therapy in treatment of non muscle invasive bladder cancer.Method:A total of 68 patients with non muscle invasive bladder cancer admitted to our hospital from January 2016 to December 2018 were randomly divided into two groups,34 cases in each group.All patients received transurethral plasmakinetic resection in our hospital,the observation group combined with Gemcitabine,the control group combined with Pirarubicin,the actual treatment effect of two groups was compared.Result:The incidence of adverse reactions in the observation group was 5.9%,which was lower than 29.4% in the control group,the difference was statistically significant (P<0.05).During the follow-up period,there was no death in the two groups.The 1-year recurrence rate was 14.7% (5/34) in the observation group and 11.8% (4/34) in the control group,there was no statistically significant difference (P>0.05).Conclusion:Transurethral plasmakinetic resection combined with Gemcitabine bladder perfusion therapy can well control the recurrence of non muscle invasive bladder cancer,and the safety performance is better than pirarubicin.
作者
崔传威
于艳
倪亮亮
杨海生
赵玉海
CUI Chuanwei;YU Yan;NI Liangliang;YANG Haisheng;ZHAO Yuhai(People’s Hospital of Pizhou City,Pizhou 221300,China)
出处
《中外医学研究》
2021年第4期130-132,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
非肌层浸润性膀胱癌
经尿道等离子电切术
吉西他滨
膀胱灌注治疗
Non muscle invasive bladder cancer
Transurethral plasmakinetic resection
Gemcitabine
Bladder perfusion therapy
